Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.

Detalles Bibliográficos
Autores principales: Park, Minah, Tan, Kelvin Bryan, Vasoo, Shawn, Dickens, Borame L., Lye, David, Cook, Alex R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984772/
https://www.ncbi.nlm.nih.gov/pubmed/35380647
http://dx.doi.org/10.1001/jamanetworkopen.2022.5750
_version_ 1784682252541624320
author Park, Minah
Tan, Kelvin Bryan
Vasoo, Shawn
Dickens, Borame L.
Lye, David
Cook, Alex R.
author_facet Park, Minah
Tan, Kelvin Bryan
Vasoo, Shawn
Dickens, Borame L.
Lye, David
Cook, Alex R.
author_sort Park, Minah
collection PubMed
description This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.
format Online
Article
Text
id pubmed-8984772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-89847722022-04-22 Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections Park, Minah Tan, Kelvin Bryan Vasoo, Shawn Dickens, Borame L. Lye, David Cook, Alex R. JAMA Netw Open Research Letter This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection. American Medical Association 2022-04-05 /pmc/articles/PMC8984772/ /pubmed/35380647 http://dx.doi.org/10.1001/jamanetworkopen.2022.5750 Text en Copyright 2022 Park M et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Park, Minah
Tan, Kelvin Bryan
Vasoo, Shawn
Dickens, Borame L.
Lye, David
Cook, Alex R.
Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title_full Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title_fullStr Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title_full_unstemmed Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title_short Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
title_sort estimated health outcomes and costs associated with use of monoclonal antibodies for prevention or mitigation of sars-cov-2 infections
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984772/
https://www.ncbi.nlm.nih.gov/pubmed/35380647
http://dx.doi.org/10.1001/jamanetworkopen.2022.5750
work_keys_str_mv AT parkminah estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections
AT tankelvinbryan estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections
AT vasooshawn estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections
AT dickensboramel estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections
AT lyedavid estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections
AT cookalexr estimatedhealthoutcomesandcostsassociatedwithuseofmonoclonalantibodiesforpreventionormitigationofsarscov2infections

Ejemplares similares